← Leaderboards
Daniel Ma
Univ Of North Carolina Chapel Hill
$559,600
Attributed
$2,238,400
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $761.5K · FY2021–23$1M$750K$500K$250K$0
'21
'22
'23
Funding mix
By agency
NIH$2,238,400 · 1
By mechanism
U01$2,238,400 · 1
Top collaborators
- Natalia Issaeva3 shared
- Kathryn Van Abel3 shared
- Wendell G Yarbrough3 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Natalia Issaeva$2,582,417
- Jennifer Below$8,898,882
- Stanley M Lemon$138,701,971
- Cary A Moody$8,050,523
- Kathryn Van Abel$559,600
Others in their field
Other Emerging Leaders on “Detection”
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Mark Marino · Venturewell$48,913,644
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
- Stuart Hellyar Hellyar$34,175,230
- Bryan Faller · Decatur Memorial Hospital$29,346,991
- Pamela Winer Goldberg · Medical Device Innovation Consortium$28,780,000
Research focus
DetectionDetection AssayAggressive TherapyAdoptionAgedCancer CenterCancer ControlCancer DetectionCancer RecurrenceAftercareBiological MarkersCervical And Uterine CancerCharacteristicsChemotherapyCisplatinClinicClinical CareClinical DiagnosisClinical TreatmentClinical TrialsCohortCommunity Clinical Oncology ProgramDefectDiagnosis
Grant awards (3)
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$735,619
U01 · FY2023 · DE
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$741,313
U01 · FY2022 · DE
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$761,468
U01 · FY2021 · DE